Pharmaceutical Technology
JANUARY 25, 2023
Clinical trials require precision and faultless execution for hypotheses to become therapies. For most of pharmaceutical history, this has made the potential benefits from outsourcing elements of these trials elusive.
Bio Pharma Dive
JANUARY 25, 2023
The veteran investors see the marriage of tech and life sciences as the “largest opportunity in venture today,” said co-founder and former Lux Capital general partner Adam Goulburn
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
JANUARY 23, 2023
The White House Office of Science & Technology Policy (OSTP) convened a listening session January 11.
Pharma Phorum
JANUARY 27, 2023
AstraZeneca’s revenue boost from COVID-19 therapy Evusheld looks set to be curbed early, as the FDA withdraws authorisation for the antibody on the grounds that it is ineffective against most subvariants now circulating in the US.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.
Pharmaceutical Technology
JANUARY 22, 2023
In 2022, the FDA approved only 37 new medicines, an underwhelming number compared to 98 in 2018. However, while only around 34% of the approvals in 2018 were for orphan drugs, 54% new approvals in 2022 were for drugs to treat rare diseases.
Bio Pharma Dive
JANUARY 23, 2023
This year could stay turbulent for the biotech sector as investors look for what the Roivant CEO described in an interview with BioPharma Dive as “safe harbors in a storm &rdquo
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Phorum
JANUARY 26, 2023
2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.
Pharmaceutical Technology
JANUARY 23, 2023
Systemic lupus erythematosus (SLE) is a systemic, inflammatory, chronic autoimmune disease that can affect multiple organs simultaneously or sequentially, with a relapsing and remitting nature.
Bio Pharma Dive
JANUARY 23, 2023
A high dose of the company’s experimental medicine appeared potent in patients with idiopathic pulmonary fibrosis, an elusive target for drugmakers. The results are from a small and short clinical trial, however
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
Pharma Phorum
JANUARY 27, 2023
Late last year, pharmaphorum caught up with Dr Karen Mullen, chief medical officer and VP of clinical & medical affairs at global drug development consultancy Boyds.
Pharmaceutical Technology
JANUARY 22, 2023
Eli Lilly and Company and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets for chronic kidney disease (CKD) in adult patients.
Bio Pharma Dive
JANUARY 23, 2023
Agency scientists are proposing to update COVID shots once a year to match circulating coronavirus strains, as well as simplifying current vaccination regimens
Pharma Mirror
JANUARY 24, 2023
Science-based innovation for manufacturing high quality cells challenges dogma and terminology Cell and gene therapies are dominating the world of drug development.
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
Pharma Phorum
JANUARY 27, 2023
Johnson & Johnson has been cleared to continue a lawsuit filed last year against drug benefit programme SaveOnSP, which claims it defrauded a payment assistance programme for patients out of “at least $100 million.”
Pharmaceutical Technology
JANUARY 26, 2023
Health Canada has accepted for review Valeo Pharma partner Veru’s new drug submission (NDS-CV) for Covid-19 therapy sabizabulin.
Bio Pharma Dive
JANUARY 24, 2023
The agency plans to convene a panel of experts on March 22 to discuss the approval application for tofersen, a closely watched medicine Biogen submitted to the FDA despite its failure in a key clinical trial
Fierce Pharma
JANUARY 26, 2023
BMS settles lawsuit with two fired employees who refused COVID vaccines kdunleavy Thu, 01/26/2023 - 14:30
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
Pharma Phorum
JANUARY 27, 2023
The emergence of COVID-19 resulted in staffing challenges that have continued to have a sustained, negative impact on clinical trial workflows.
Pharmaceutical Technology
JANUARY 25, 2023
A researchers’ team from the University of Texas at San Antonio’s (UTSA) Department of Chemistry and its partners are developing compounds to treat Glioblastoma multiforme (GBM) tumours. UTSA’s partners include UT Health San Antonio’s Department of Obstetrics and Gynecology and Mays Cancer Center.
Bio Pharma Dive
JANUARY 24, 2023
The drugmaker reported fourth quarter revenue that fell short of forecasts, but reiterated confidence in reaching a $60 billion pharmaceutical sales goal
Intouch Solutions
JANUARY 26, 2023
M eet Meg Bradley, Senior Art Director at EVERSANA INTOUCH. Meg has been with EVERSANA INTOUCH for more than 5 years and has held a variety of positions.
Pharma Phorum
JANUARY 26, 2023
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.
Pharmaceutical Technology
JANUARY 27, 2023
The European Union (EU) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (trastuzumab deruxtecan) as monotherapy to treat unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer adult patients.
Bio Pharma Dive
JANUARY 27, 2023
The FDA gave the top-selling immunotherapy a broad label in adjuvant lung cancer despite mixed results in the main study supporting its application, taking one Wall Street analyst by surprise
Outsourcing Pharma
JANUARY 24, 2023
Research emerging from the University of Toronto found that using machine learning models was able to guide the design of long-acting drug formulations. Clinical Development
Pharma Phorum
JANUARY 26, 2023
Guidance on the way pharma companies communicate about prescription medicines has been updated in the UK to cover use of social media channels for the first time.
Pharmaceutical Technology
JANUARY 24, 2023
The US Food and Drug Administration (FDA) has granted clearance for Neurogene’s investigational new drug (IND) application for NGN-401 to treat Rett syndrome.
Bio Pharma Dive
JANUARY 24, 2023
The company blamed a range of factors in its decision, including limited funding, slower-than-anticipated trial enrollment and “broader sector trends &rdquo
Pharma Times
JANUARY 27, 2023
Therapy involves patients with paediatric-onset hypophosphatasia – a rare bone disease
Pharma Phorum
JANUARY 27, 2023
As the legendary investor Warren Buffett once said, forecasts about the future usually tell you more about the forecaster than they do about the future.
Pharmaceutical Technology
JANUARY 25, 2023
After a tumultuous year that weathered the continued impact of a bear market , many in biotech are looking for signs of improvement in 2023. However, industry experts have buckled up in anticipation of continued challenges this year.
Bio Pharma Dive
JANUARY 25, 2023
The former Biogen head is retiring after taking Vir from a small startup to a publicly traded developer of infectious disease drugs. Bayer executive Marianne De Backer will succeed him
Expert insights. Personalized for you.
147 
Let's personalize your content